Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIISupportive careCompleted18 and overNCI, OtherCDR0000257027
NCCTG-N00C1, NCI-P02-0232, MC00C8, 1497-00, N00C1, NCT00046904

Trial Description


RATIONALE: Etanercept is a substance that is being studied as a treatment for cachexia (weight loss) and anorexia (lack of appetite) in patients who have cancer. It is not yet known whether etanercept is effective in improving cancer-related cachexia and anorexia.

PURPOSE: Randomized phase III trial to determine the effectiveness of etanercept in treating cancer-related cachexia and anorexia in patients who have advanced cancer.

Further Study Information


  • Compare etanercept vs placebo in the treatment of cancer-related cachexia and anorexia, in terms of weight measurement and rate of weight change, in patients with advanced malignancies.
  • Determine the effect of this drug on nausea and vomiting in these patients.
  • Assess the functional status and appetite of patients treated with this drug.
  • Assess the quality of life of patients treated with this drug.
  • Determine the toxic effects of this drug in these patients.
  • Determine whether this drug prolongs survival of these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to primary malignant disease (lung vs gastrointestinal vs other), severity of weight loss (less than 4.6 kg vs at least 4.6 kg), planned concurrent chemotherapy (yes vs no), age (less than 50 vs 50 and over), gender, planned use of megestrol or other progestational agent (yes vs no), and GBU Prognostic Index (good vs bad vs unsure). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive etanercept subcutaneously (SC) twice weekly.
  • Arm II: Patients receive placebo SC twice weekly. Treatment in both arms continues for a maximum of 24 weeks in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, weekly for 1 month, and then monthly during treatment.

Patients are followed every 6 months for 5 years.

PROJECTED ACCRUAL: A total of 274 patients (137 per treatment arm) will be accrued for this study within 19 months.

Eligibility Criteria


  • Histologically or cytologically confirmed malignancy except brain cancer
  • If the patient has multiple primaries or an unknown primary, the currently active cancer cannot be brain cancer
  • Disease considered incurable with available therapies
  • No clinical evidence of ascites
  • Weight loss of at least 5 pounds (2.3 kg) within the past 2 months (excluding perioperative weight loss) and/or estimated caloric intake of less than 20 cal/kg daily
  • Weight gain determined by physician to be beneficial
  • Patient perceives weight loss as a problem



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • More than 3 months


  • Not specified


  • Not specified


  • Not specified


  • No poorly controlled congestive heart failure
  • No poorly controlled hypertension
  • No pacemaker, implanted defibrillator, stents, or metal suture material in the heart or great vessels (for patients participating in the BIA translational portion of the study)


  • No known mechanical obstruction of the alimentary tract
  • No malabsorption
  • No intractable vomiting (more than 5 episodes/week)
  • Not concurrently receiving tube feedings or parenteral nutrition


  • Able to reliably administer subcutaneous medication twice weekly
  • Alert and mentally competent
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy

  • More than 1 month since prior infliximab
  • No concurrent live vaccination


  • Concurrent chemotherapy allowed

Endocrine therapy

  • At least 1 month since prior adrenal steroids
  • No concurrent adrenal steroids (inhalant, topical, or optical steroids allowed)
  • Concurrent short-term dexamethasone for chemotherapy-induced emesis is allowed


  • Concurrent radiotherapy allowed


  • Not specified


  • More than 1 month since prior etanercept
  • No concurrent evaluation with another device that injects an electrical current into the body (for patients participating in the bioelectrical impendance analysis [BIA] translational portion of the study)

Trial Contact Information

Trial Lead Organizations/Sponsors

Mayo Clinic Cancer Center

  • National Cancer Institute
Aminah Jatoi, Study Chair

Link to the current record.
NLM Identifier NCT00046904 processed this data on April 09, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to